Physician profile
Jie Ling
NPI 1003187766
$9,420.61
in general payments reported to CMS, 2019-2025
38 companies · $2,221 in 2025
The $2,221 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,826 · 2020: $838 · 2021: $1,016 · 2022: $1,382 · 2023: $999 · 2024: $1,140 · 2025: $2,221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,359.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,849.26 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,025.99 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Janssen Pharmaceuticals, INC | $836.94 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $818.29 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $687.51 | 2019-2025 | Evenity, Prolia, Otezla |
| Merck Sharp & Dohme LLC | $607.87 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $558.06 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $445.65 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Gilead Sciences, INC. | $355.49 | 2019-2025 | Vemlidy |
| Idorsia Pharmaceuticals US INC | $258.08 | 2023-2024 | Quviviq |
| Janssen Scientific Affairs, LLC | $248.52 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $234.21 | 2024-2025 | Zoryve |
| Amarin Pharma, INC. | $203.09 | 2020-2021 | |
| Genzyme Corporation | $188.95 | 2019-2025 | |
| Abbvie INC. | $151.56 | 2019-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertos Medical, INC. | $131.58 | 2022 | |
| Pfizer INC. | $96.03 | 2022-2024 | |
| Genentech USA, INC. | $77.10 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $67.22 | 2019 | |
| Phathom Pharmaceuticals, INC. | $60.92 | 2024 | Voquezna |
| Abbott Laboratories | $59.77 | 2021-2022 | |
| Astellas Pharma US INC | $48.45 | 2019-2023 | Veozah |
| Allergan, INC. | $46.91 | 2021-2022 | |
| Ucb, INC. | $42.60 | 2019 | |
| Terumo Bct, INC. | $31.79 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $29.75 | 2019 | |
| Biogen, INC. | $28.80 | 2025 | Zurzuvae |
| Regeneron Healthcare Solutions, INC. | $25.71 | 2019 | |
| Averitas Pharma INC. | $25.58 | 2024 | Qutenza |
| Tersera Therapeutics LLC | $23.86 | 2025 | Zoladex |
| Edwards Lifesciences Corporation | $22.47 | 2025 | Sapien 3 Ultra Resilia |
| Boston Scientific Corporation | $22.34 | 2022 | |
| Esperion Therapeutics, INC. | $21.97 | 2025 | Nexletol |
| Seqirus USA INC | $20.64 | 2025 | Fluad, Flucelvax |
| Alexion Pharmaceuticals, INC. | $19.11 | 2020 | |
| Sanofi-Aventis U.S. LLC | $19.11 | 2022 | |
| Arbor Pharmaceuticals, INC. | $16.51 | 2021 | |
| Hikma Pharmaceuticals USA | $12.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jie Ling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.